Navigation Links
Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury
Date:11/17/2014

MENLO PARK, Calif., Nov. 17, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane S. Lebkowski, Ph.D., Asterias' President of Research and Development, will participate in a live Google Hangout session presented by the California Institute for Regenerative Medicine (CIRM) discussing the latest progress in stem cell-based therapies for spinal cord injury (SCI).

The CIRM Google Hangout session is scheduled for Tuesday, November 18, 2014, from 12:00 to 1:00pm PT (3:00 to 4:00pm ET). To access the event, please visit http://bit.ly/1sh1Dsm.

The session will include a discussion of Asterias' CIRM-funded Phase 1/2a dose escalation clinical trial for SCI. In addition to Dr. Lebkowski, participants include Roman Reed, a tireless advocate for stem cell research and SCI treatments, and Kevin Whittlesey, Ph.D., a CIRM science officer. Mr. Reed will provide the patient advocate community's perspectives, and Dr. Whittlesey will discuss other CIRM-funded research that aims to better understand SCI and to bring stem cell-based therapies to clinic trials.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's core technologies center on pluripotent stem cells, which are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat diseases or serious injuries in several medical areas where there is high unmet medical need and without adequate available therapies. Asterias' two clinical development programs, AST-OPC1 (oligodendrocyte progenitor cells) for spinal cord injuries and AST-VAC2 (antigen-presenting allogeneic dendritic cells) for lung cancer, are based on the Company's proprietary technology platforms of Pluripotent Stem Cells and Allogeneic Dendritic Cell Immunotherapy, respectively. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.  

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Asterias Biotherapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury
2. Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
3. Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
4. Northwest Biotherapeutics Completes Public Offering Of Common Stock And Warrants; Underwriter Exercises Full Over-Allotment
5. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
6. Healthpoint Biotherapeutics To Assume Smith & Nephew Name
7. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
8. Northwest Biotherapeutics Announces Registered Direct Offering
9. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
10. iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship
11. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2019)... ... April 18, 2019 , ... ChronWell, ... it has been invited to participate in the inaugural “RIMS Tech, the Insurtech ... coming to Boston April 28th through May 1st. , The competition, which ...
(Date:4/18/2019)... ... April 18, 2019 , ... ... shaping Cultural Beliefs®, and solving Accountability Gaps, and that is now introducing cutting-edge ... team as a service provider to the FDA. This award, estimated at ...
(Date:4/17/2019)... ... April 17, 2019 , ... Salt Lake Community ... Doctorate recipients. They will receive their degrees at SLCC’s May 3 Commencement at the ... executive vice president over Corporate Affairs and Miller Family Philanthropy. Richards is president and ...
Breaking Medicine Technology:
(Date:4/18/2019)... ... April 18, 2019 , ... She went from learning disabled to honor ... her mother, Cheryl Reilly. Those “goofy tests,” performed by Deborah Zelinsky, O.D. , ... years old, had such narrow range of visual awareness, she could only see what ...
(Date:4/17/2019)... ... April 17, 2019 , ... With Fentanyl overdose deaths continuing to ... curb the death toll by looking for an alternative to naloxone. Researchers are presenting ... Exposition this week. , Naloxone (often known by the name brand Narcan) has been ...
(Date:4/17/2019)... ... April 17, 2019 , ... The ... new initiative this April to designate April 19th as World IBS Day to ... research & healthcare professionals in their pursuit to find treatments. Irritable Bowel Syndrome ...
(Date:4/17/2019)... (PRWEB) , ... April 17, 2019 , ... ... focus on advances in revolutionary diagnostic technologies. This episode is scheduled to air ... In this segment, Innovations will focus on Credo Biomedical Pte. Ltd. (Credo Biomedical), ...
(Date:4/17/2019)... Calif. (PRWEB) , ... April 17, 2019 , ... Student-athletes ... edge thanks to a 2019 Thomas R. Brown Athletics Grant from California ... equipment, improve player safety, and provide uniforms. , The grant is named for ...
Breaking Medicine News(10 mins):